COVID-19: impact on biotech R&D in Spain 2020
More than 55 percent of the biotechnology companies surveyed by the Spanish Bioindustry Association (ASEBIO) stated that COVID-19 had adversely affected research and development due to delayed projects and objectives. In contrast, 16.42 percent answered that COVID-19 had a positive impact because it opened new projects and speeded-up plans.